<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="3544"><DrugName>LY-255283</DrugName><DrugSynonyms><Name><Value>CGS-23356</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LY-177455</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LY-255283</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>117690-79-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3544" type="Drug"><TargetEntity id="142927" type="siDrug">LY-255283</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="132" type="Action"><TargetEntity id="405" type="Mechanism">Cyclooxygenase (COX) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3166" type="Action"><TargetEntity id="238" type="Mechanism">Leukotriene BLT (LTB4) Antagonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsPrimary><Action id="3166">Leukotriene BLT receptor antagonist</Action><Action id="132">Cyclooxygenase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="2953">Anti-inflammatory</Action><Action id="2955">Non-steroidal anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra><Ephmra><Code>M1A3</Code><Name>Coxibs</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-30T09:33:02.000Z</LastModificationDate><ChangeDateLast>2008-10-07T10:26:32.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Lilly was evaluating &lt;ulink linkID="3544" linkType="Drug"&gt;LY-255283&lt;/ulink&gt; (structure shown), an LTB4 antagonist, for the potential treatment of inflammatory disorders, such as asthma, rheumatoid arthritis and psoriasis [&lt;ulink linkID="13103" linkType="reference"&gt;13103&lt;/ulink&gt;]. However, development has been discontinued [&lt;ulink linkID="258036" linkType="reference"&gt;258036&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1991-12-01T00:00:00.000Z</StatusDate><Source id="13103" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>1991-12-01T00:00:00.000Z</StatusDate><Source id="13103" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1991-12-01T00:00:00.000Z</StatusDate><Source id="13103" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00535"><Name>Cyclooxygenase</Name><SwissprotNumbers/></Target><Target id="PTGT-01229"><Name>Leukotriene BLT receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CCc1cc(c(cc1OCCCCCC(C)(C)c2[nH]nnn2)O)C(=O)C</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2198273" number="WO-2008117970" title="Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers"/><PatentFamily id="518783" number="WO-2009105723" title="Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway"/><PatentFamily id="553563" number="WO-2008117971" title="Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea University Foundation" id="1013186"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Accelalox Inc" id="1030879"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Research Foundation" id="1086673"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>